As a premier contract research organization (CRO), CrownBio has deep industry relationships and a global footprint that will complement JSR’s already global presence.
Recently published work in the Journal of Endocrinological Investigation and Nature’s Scientific Reports demonstrates the advantages of a new method using DSI’s HD-XG implantable glucose device and...
These joint publications illustrate the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
The data derived from studies using CrownBio’s portfolio showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy tes...
CrownBio will add a significant number of cell lines and reference standards related to EGFR, KRAS, and BRAF signaling cascades of the MAPK pathway, which plays a critical role in the development a...
“The publication of these papers are indicative of how CrownBio continues to further validate the translatability of this model and our commitment to bring to the market novel models that are more ...
Researchers at JAX will immediately begin leveraging CrownBio’s vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.
CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio’s proprietary 10B10 antibody.
CrownBio will present data on its latest scientific developments including the impact of intestinal microbiota on anti-PD-L1 immunotherapy, the development of primary tumor allograft models for pre...
7 of 11
Receive JSR Life Sciences news on your RSS reader.
